Neurochirurgische Klinik und Poliklinik
Refine
Is part of the Bibliography
- yes (214)
Year of publication
Document Type
- Journal article (148)
- Doctoral Thesis (63)
- Report (2)
- Review (1)
Keywords
- Neurobiologie (41)
- Glioblastom (11)
- glioblastoma (11)
- Medizin (9)
- Glioblastoma (6)
- Vestibularisschwannom (6)
- vestibular schwannoma (6)
- Schädel-Hirn-Trauma (5)
- Subarachnoidalblutung (5)
- active zone (5)
- astrocytoma (5)
- deep brain stimulation (5)
- glioblastoma multiforme (5)
- glioma (5)
- Akustikustumor (4)
- Durchblutung (4)
- Gehirn (4)
- Gliom (4)
- Neurochirurgie (4)
- Parkinson's disease (4)
- brain (4)
- rats (4)
- recurrence (4)
- subthalamic nucleus (4)
- therapy (4)
- Astrozytom (3)
- CXCR4 (3)
- Glioblastoma multiforme (3)
- Hypothalamus (3)
- MGMT (3)
- Prostaglandine (3)
- TRH (3)
- TTFields (3)
- Tumortherapiefelder (3)
- blood pressure (3)
- blood-brain barrier (3)
- brain tumor (3)
- mRNA (3)
- medulloblastoma (3)
- meningioma (3)
- metabolism (3)
- mice (3)
- neuroprotection (3)
- protein (3)
- rat (3)
- relapse (3)
- traumatic brain injury (3)
- ABR (2)
- ADAM9 (2)
- ATF5 (2)
- Akustikusneurinom (2)
- Aneuploidie (2)
- Blut-Hirn-Schranke (2)
- CA3 (2)
- CNS disorders (2)
- COVID-19 (2)
- Delta-Valve (2)
- Elektrocochleographie (2)
- Elektrophysiologie (2)
- Glioma (2)
- Hirntumor (2)
- Hydrocephalus (2)
- Hyperkapnie (2)
- Hypothermie (2)
- Lipopolysaccharide (2)
- MACC1 (2)
- MPS1 (2)
- MRI (2)
- Merlin (2)
- Mesenteric circulation (2)
- Mitose (2)
- NMR-Tomographie (2)
- Neuralgie (2)
- Neurofibromatose (2)
- Neurophysiologie (2)
- Neuroprotektion (2)
- Overdrainage (2)
- Parkinson’s disease (2)
- RIM1α (2)
- Ratte (2)
- SAH (2)
- Sagittalnahtsynostose (2)
- Schmerz (2)
- Stroke (2)
- TTK (2)
- Tumor Treating Fields (TTFields) (2)
- Tumor-Nekrose-Faktor <alpha> (2)
- Unishunt (2)
- VEGF (2)
- acute brain slices (2)
- animal model (2)
- blood–brain barrier (2)
- brain edema (2)
- cancer stem cells (2)
- cardiac output (2)
- cerebEND (2)
- closed head injury (2)
- contact-kinin system (2)
- depression (2)
- dopamine (2)
- electron tomography (2)
- expression (2)
- factor XII (2)
- fluoroscopy (2)
- heart rate (2)
- high-pressure freezing/freeze substitution (2)
- imaging (2)
- inflammation (2)
- intraoperative imaging (2)
- intraoperative monitoring (2)
- local field potentials (2)
- low-grade glioma (2)
- mRNA expression (2)
- minocycline (2)
- neuropathic pain (2)
- organoids (2)
- pain (2)
- pathogenesis (2)
- presynaptic (2)
- radiotherapy (2)
- temozolomide (2)
- tumor necrosis factor (2)
- 2 PM (1)
- 2-photon microscopy (1)
- 3 D rotational fluoroscopy (1)
- 3D cell culture (1)
- 3D ex vivo models (1)
- 3D fluoroscopy (1)
- 3D in vitro model (1)
- 3D-Modell (1)
- ABR Monitoring (1)
- Akustisch evozierte Potentiale (1)
- Akustisch evoziertes Potenzial (1)
- Anaphylactic shock (1)
- Anaphylaxis (1)
- Aneurysma (1)
- Apoptosis (1)
- Astrocytic tumor (1)
- Astrocytoma (1)
- Astrozytäre Tumore (1)
- Audiologie (1)
- Auditory brainstem implant (1)
- Augenhintergrund (1)
- Autoradiography (1)
- Axonal degeneration (1)
- BDNF (1)
- BN 52021 (1)
- BRMS1 (1)
- Bauchaorta (1)
- Bevacizumab (1)
- Biomarker (1)
- Biowissenschaften (1)
- Blood–brain barrier (1)
- Blutdruck (1)
- Bone chips (1)
- Bradykininantagonist (1)
- Brain stem (1)
- Bruchpilot (1)
- C1-Inhibitor Berinert (1)
- C1-inhibitor (1)
- C6 (1)
- C6 cells (1)
- C6-Zellen (1)
- CA-IX (1)
- CA2+ channels (1)
- CA3 pyrimidal cells (1)
- CAD-CAM (1)
- CBF (1)
- CD133 (1)
- CNS cancer (1)
- CNS diseases (1)
- CRPS (1)
- CSVD (1)
- CX3CL1 (1)
- CXCL12 (1)
- CXCL13 (1)
- Cardiovascular (1)
- Cardiovascular system (1)
- Cefotaxim (1)
- Cell cycle regulation (1)
- Cerebral Ischemia (1)
- Cerebral-ischemia (1)
- Cranial window (1)
- Crespi effect (1)
- Cytokine (1)
- DBS biomarkers (1)
- DBS programming (1)
- Dekompressionsoperation (1)
- Delayed cerebral infarction (1)
- Delayed ischemic neurological deficit (1)
- Demenz (1)
- Detektion (1)
- Diabetische Polyneuropathie (1)
- Doxycyclin (1)
- Drosophila melanogaster (1)
- E-cadherin (1)
- ECoG (1)
- ED2 (1)
- EEG (1)
- EPO (1)
- EVAR (1)
- Early Brain Injury (1)
- Electric auditory brainstem response (1)
- Endothelial cell (1)
- Endothelium (1)
- Endothelzelle (1)
- Endurant® (1)
- Erythropoetin (1)
- Experimentaltumor (1)
- Expression (1)
- Exzitatorische Synapse (1)
- FAEP (1)
- FTY720 (1)
- Facialisl�hmung (1)
- Facialisparese (1)
- Feinmotorik (1)
- Fibrin glue (1)
- Fluorescence (1)
- Focal brain ischemia (1)
- Frühphase nach experimenteller Subarachnoidalblutung (1)
- Genetik (1)
- Genexpression (1)
- Glioblastoma cell line (1)
- Glioblastomas (1)
- Glioma stem cells (1)
- Granulozyten-Makrophagen-koloniestimulierender Faktor Leukomax (rekombinant hergestelltes Präparat) (1)
- Graphiktablett (1)
- HBMVEC (1)
- HBMVEC Zellkultur (1)
- HBO (1)
- HERV-K (1)
- HIF-1 (1)
- Head-injury (1)
- Hemodynamic depression (1)
- Hemorrhage (1)
- Hippocampus (1)
- Hirnblutung (1)
- Hirndruck (1)
- Hirnödem (1)
- Histologie (1)
- Human endogenous retrovirus (1)
- Hydroxyethylstärke (1)
- Hyper-HES (1)
- Hypertension (1)
- Hypophyse (1)
- Hypophysenhormon (1)
- Hypoxia (1)
- Hypoxie (1)
- Hörprothese (1)
- Hörrehabilitation (1)
- IBA-1 (1)
- IDH (1)
- IDH1/2 (1)
- IL-6 (1)
- IOM (1)
- ISBI (1)
- Icosanoid (1)
- Immunhistochemie (1)
- Immunostimulatory adjuvant (1)
- Immunotherapy (1)
- Impressiones digitatae (1)
- In vitro models (1)
- In vivo imaging (1)
- In-vivo dia lysis (1)
- Indikationsstellung (1)
- Infiltration (1)
- IntelliCage (1)
- Intercellular adhesion molecule 1 (1)
- Interleukin 1 beta Neutralisierung (1)
- Interleukin 1-beta (1)
- Intraoperatives Monitoring (1)
- Intravascular coagulation (1)
- Intravital imaging (1)
- Invasion (1)
- Irradiation (1)
- KIF (1)
- KIF11 (1)
- Kephalometrie (1)
- KiSS1 (1)
- Kleinhirn-Brückenwinkeltumor (1)
- Kleinhirnbrückenwinkel (1)
- Kleinhirnbrückenwinkeltumor (1)
- Knochentumor (1)
- Kognition (1)
- Komplikation (1)
- Komplikationen (1)
- Kontakt-Kinin-System (1)
- Kraniopharyngeom (1)
- Kranioplastik (1)
- Kraniosynostose (1)
- Körperachse (1)
- LGA (1)
- LTD (1)
- Langzeitdepression (1)
- Lateral suboccipital craniectomy (1)
- Lebensqualität (1)
- Lipoxin (1)
- Literatur (1)
- Locus coeruleus (1)
- Low grade Astrocytoma (1)
- MEA (1)
- MGMT promoter methylation (1)
- MMP (1)
- MMP9 (1)
- MRT (1)
- Mad2A und Mad2B (1)
- Makrophagen (1)
- Mapping <Medizin> (1)
- Marklager (1)
- Matrix-Metalloprotease (1)
- Matrixmetalloproteinasen (1)
- Medulloblastom (1)
- Medulloblastome (1)
- Meningeom (1)
- Metalloproteinasen (1)
- Metastatic breast cancer (1)
- Methylierung (1)
- Methylprednisolon (1)
- Mice (1)
- Microbubbles (1)
- Microinjection (1)
- Mikrochirurgie (1)
- Minozyklin (1)
- Model (1)
- Molecular-weight heparin (1)
- Monocyte (1)
- Monopolar spindle 1 (1)
- Morbus Fabry (1)
- Motorischer Cortex (1)
- Mouse model (1)
- Multielectrode Array (1)
- Multielektroden Arrays (1)
- Myelographie (1)
- Myelopathie (1)
- N-Acetyl-leukotriene E4 (1)
- NADPH oxidases (NOX) (1)
- NCH93 (1)
- NDRG1 (1)
- NF-2 (1)
- NF2-related schwannomatosis (NF2) (1)
- NT-3 (1)
- Neoangiogenese (1)
- Nervus facialis (1)
- Nervus vestibulocochlearis (1)
- Nestin (1)
- Neugeborenes (1)
- Neurodegeneration (1)
- Neurofibromatose Typ 2 (1)
- Neuroinflammation (1)
- Neurologie (1)
- Neuromonitoring (1)
- Neuronale Netzwerke (1)
- Neuronale Plastizität (1)
- Neuronavigation (1)
- Neuronclusters (1)
- Neurons (1)
- Neuropeptides (1)
- Neuroprotection (1)
- Neurotrophe Faktoren (1)
- Neurowissenschaften (1)
- Notfall (1)
- O(6)-Methylguanine-DNA Methyltransferase (1)
- O-Arm (1)
- Oncolysis (1)
- Onkologie (1)
- Osteogeneration (1)
- Osteopontin (1)
- Outcome (1)
- PAF-acether (1)
- PCDHGC3 (1)
- PCR analysis (1)
- PDH (1)
- PET (1)
- PET/CT (1)
- PFA in ethanol (1)
- PMMA (1)
- Paclitaxel (1)
- Pds5A und Pds5B (1)
- Pedikelschraube (1)
- Pentixafor (1)
- Peptide-leukotrienes (1)
- Phase II trials (1)
- Physiologie (1)
- Polymethylmethacrylate (1)
- Polyneuropathie (1)
- Proliferation (1)
- Prostaglandins (1)
- Proteasomenaktivator (1)
- Pyruvatdehydrogenase-Komplex (1)
- R-715 (1)
- RECK (1)
- RIM-binding protein (1)
- RPS27 (1)
- RS-13 (1)
- Rat hippocampus (1)
- Rats (1)
- Real time quantitative PCR (1)
- Regression (1)
- Rehabilitation (1)
- Renal circulation (1)
- Reperfusion (1)
- Resektion (1)
- Revision (1)
- Rezeptor Tyrosin Kinase (1)
- SARS-CoV-2 (1)
- SHRSP (1)
- SOAT1 (1)
- SSEP (1)
- SV pool (1)
- Schmerzforschung (1)
- Schrauben-Stab-Osteosynthese (1)
- Schraubenlage (1)
- Schädelchirurgie (1)
- Schädelnaht (1)
- Silver degeneration staining (1)
- Slice Culture (1)
- Spinal dissemination (1)
- Spinalkanalstenose (1)
- Spindle assembly checkpoint (1)
- Staphylococcus (1)
- Star-PEG (1)
- Stauungspapille (1)
- Stentgraft (1)
- Störungen der Feinmotorik (1)
- Subarachnoid hemorrhage (1)
- Subarachnoidalblutung Neuroprotektion Frühphase Nitroprussid Notfall (1)
- Supraoptic nucleus (1)
- Surgery (1)
- Sympathetic nervous system (1)
- Synaptische Transmission (1)
- Synaptische Vesikel (1)
- T-2 toxin (1)
- TBI (1)
- TNF (1)
- TNF-α (1)
- TSPO (1)
- Taxol (1)
- Temozolomide (1)
- Therapie (1)
- Thromboplastin (1)
- Thrombus formation (1)
- Thyreotropin-Releasinghormon (1)
- Tiermodell (1)
- Tierversuch (1)
- Trauma (1)
- Traumatic brain injury (1)
- Trepanation (1)
- Tumor (1)
- Tumor Treating Fields (1)
- Tumor-Nekrose-Faktor (1)
- Tumor-Nekrose-Faktor <alpha>-Inhibitor (1)
- Tumor-Treating Fields (TTFields) (1)
- Tumorentstehung (1)
- Tumorinvasion (1)
- Tumorwachstum (1)
- Ultraschall (1)
- Uniparentale Stammzellen (1)
- VLSM (1)
- Vaskularisation (1)
- Vasopressin (1)
- Ventilation (1)
- Vincristin (1)
- Voluven (1)
- Von Willebrand factor (1)
- WNT signaling (1)
- Willebrand-Faktor (1)
- Wirbelkanalstenose (1)
- Wirbelsäule (1)
- Wolkenschädel (1)
- Zdichavsky (1)
- Zell-Adhäsionsmolekül (1)
- Zellkultur (1)
- Zellzyklusregulation (1)
- Zervikale Myelopathie (1)
- [3H][3Me-His2]-TRH (1)
- \(^{68}\)Ga-Pentixafor (1)
- accelerator based radiosurgery (1)
- acoustic (1)
- acoustic neuroma (1)
- acoustic startle (1)
- adherence (1)
- adolescence (1)
- aerobic glycolysis (1)
- aesthetic results (1)
- aging (1)
- alkaline phosphatase (1)
- amplitude criterion (1)
- amyloidoma (1)
- anaplastic medulloblastoma (1)
- aneurysm (1)
- aneurysmatisch (1)
- anodic stimulation (1)
- anticancer activity (1)
- anxiety (1)
- asfotase alfa (1)
- assoziative Paarstimulation (1)
- astocytoma (1)
- astrocytes (1)
- astrocytic tumor (1)
- astroglia (1)
- atrial fibrillation (1)
- audiometry (1)
- auditory brainstem responses (1)
- autoradiography (1)
- beaten copper markings (1)
- behavior (1)
- benzodiazepine antagonist. (1)
- beta oscillations (1)
- beta power (1)
- beta-catenin (1)
- blastocysts (1)
- blood brain barier (1)
- blood brain barrier (1)
- blood nerve barrier (1)
- blood-brain-barrier (1)
- body axis (1)
- bone (1)
- bradykinin (1)
- bradykinin antagonist (1)
- brain development (1)
- brain-injury (1)
- brainstem auditory evoked potentials (1)
- braintumor (1)
- c6 (1)
- cancer (1)
- catecholamlnes (1)
- cefotaxime (1)
- cerebEND Zellkultur (1)
- cerebEND cells (1)
- cerebraI ischemia (1)
- cerebraler Blutfluss (1)
- cerebrovascular disorders (1)
- cerebrovascular surgery (1)
- cerebrovaskuläre Chirurgie (1)
- cervical spine (1)
- chemokine receptor-4 (1)
- chemotherapy (1)
- childhood (1)
- children (1)
- chlorisondamine (1)
- chronic heart failure (1)
- chronic stimulation (1)
- cip (1)
- claudin-1 (1)
- clinical trials (1)
- cognitive function (1)
- cognitive functions (1)
- cognitive impairment (1)
- coherence analysis (1)
- communicating networks (1)
- compaction (1)
- complications (1)
- craniofacial orthodontics (1)
- craniopharyngioma (1)
- cranioplasty (1)
- craniovertebral junction (1)
- critical-illness-polyneuropathie (1)
- ct-scan (1)
- cytokine (1)
- cytokines (1)
- dSTORM (1)
- damage control orthopedics (1)
- deafness (1)
- deformational cranial asymmetry (1)
- dementia (1)
- dennorphin (1)
- derivation (1)
- dermorphin (1)
- dexamethasone (1)
- differentiation (1)
- diffuse (1)
- diffuse astrocytoma (1)
- digitales Graphiktablett (1)
- direct cortical stimulation (1)
- directional deep brain stimulation (1)
- distress (1)
- double-blind (1)
- doxycycline (1)
- early brain injury (1)
- early detection (1)
- edema (1)
- electrocochleography (1)
- erythropoietin (1)
- etanercept (1)
- executive function (1)
- experimental stroke (1)
- expression pattern (1)
- facial nerv (1)
- femoral fracture (1)
- flumazenil (1)
- focal (1)
- focal brain lesion (1)
- focal cerebral-ischemia (1)
- frameless systems (1)
- frühe ischämische Ereignisse (1)
- frührehabilitation (1)
- gamma knife radiosurgery (1)
- glia (1)
- glioblastoma cell-lines (1)
- glioblastoma multiforme (GBM) (1)
- gliom (1)
- glucocorticoid receptor (1)
- group 3 (1)
- guidelines (1)
- head (1)
- hearing preservation (1)
- hemorrhagic shock (1)
- high-pressure freezing (1)
- hippocampal (1)
- hippocampal mossy fiber bouton (1)
- histological findings (1)
- homeostasis (1)
- human brain microvascular endothelial cells (HBMVEC) (1)
- human cells (1)
- hypophosphatasia (1)
- hypothermia (1)
- hypovolemic hypotension (1)
- hypoxia (1)
- image-guided programming (1)
- immunofluorescence (1)
- immunofuorescence double staining (1)
- immunohistochemistry (1)
- in vitro (1)
- in vitro model (1)
- in vivo (1)
- in-vitro (1)
- in-vivo (1)
- induced stem cells (1)
- induzierte Stammzellen (1)
- infants with deformational plagiocephaly (DP) (1)
- infiltration (1)
- inflammatory mechanisms (1)
- integrin (1)
- internalized stigmatization (1)
- intracranial pressure (1)
- intraoperatives Monitoring (1)
- invasion (1)
- ischemia (1)
- ischemic events (1)
- isoliert (1)
- isosteviol sodium (1)
- isosteviol sodium (STVNA) (1)
- kallikrein–kinin system (1)
- kinematische Parameter (1)
- kinesin (1)
- kinin receptor (1)
- kinin receptors (1)
- knock down (1)
- kognitive Beeinträchtigung (1)
- lesion symptom mapping (1)
- lines (1)
- lipid droplets (1)
- liponeurocytoma (1)
- lipopolysaccharides (1)
- liquid biopsy (1)
- literature (1)
- lnflammation (1)
- locus coeruleus (1)
- long-term depression (1)
- lower grade glioma (1)
- macrophages (1)
- management (1)
- mapping (1)
- matrix metalloproteinase (1)
- matrix-metalloproteinase (1)
- mechanism of action (1)
- memory (1)
- metastasis (1)
- metastasis associated in colorectal cancer 1 (MACC1) (1)
- metastasis-associated in colon cancer 1 (MACC1) (1)
- methylation (1)
- methylprednisolone (1)
- microRNA (1)
- microglia (1)
- microsurgery (1)
- mikrochirurgische Resektion (1)
- minimally invasive (1)
- mitotane (1)
- modulation (1)
- molecular imaging (1)
- molecular signature (1)
- mononuclear phagocytes (1)
- mortality (1)
- mossy fiber synapse (1)
- mossy fiber synapses (1)
- motor control (1)
- motor cortex (1)
- mouse-brain (1)
- movement (1)
- movement disorders (1)
- mri (1)
- multifocal growth (1)
- multiple sclerosis (1)
- mycotoxin (1)
- myocardial infarction (1)
- naloxonazine (1)
- naloxone (1)
- nanotopology (1)
- nausea and emesis (1)
- neoangiogenesis (1)
- neonatal (1)
- nervous-sytem (1)
- neuonal differentiation (1)
- neural stem-cells (1)
- neurobehavioral deficits (1)
- neurocytoma (1)
- neurodegenerative disease (1)
- neurofibromatosis (1)
- neurofibromatosis type 2 (1)
- neuroinflammation (1)
- neurological complications (1)
- neurology (1)
- neuroma (1)
- neuromuscular junction (1)
- neuronal damage (1)
- neuronal plasticity (1)
- neuronale Differenzierung (1)
- neuronavigation (1)
- neurooncology (1)
- neuropathy (1)
- neuropsychologische Testbatterie (1)
- neurosurgery (1)
- neurotrophic factor (1)
- neurovascular disorders (1)
- neurovascular unit (1)
- non-VKA oral anticoagulants (1)
- non-small cell lung cancer (NSCLC) (1)
- nucleus (1)
- object recognition memory (1)
- obsessive-compulsive disorder (1)
- occupation (1)
- oligodendroglioma (1)
- opiates (1)
- opioid peptides (1)
- opioid receptors (1)
- opioid-benzodiazepine interactions (1)
- organotypic hippocampal slice cultures (OHSC) (1)
- orthotopic xenograft (1)
- osteomalacia (1)
- outcome (1)
- ovarian cancer (1)
- oxidative stress (1)
- paclitaxel (1)
- paediatric cancer (1)
- painful neuropathy (1)
- paired associative stimulation (1)
- palladium (1)
- pancreatic cancer (1)
- papilledema (1)
- paragangliomas (1)
- pedicle screws (1)
- peptide receptor radionuclide therapy (PRRT) (1)
- physical examination (1)
- plasticity (1)
- platelet activating factor (1)
- platelet-activating factor (1)
- platform (1)
- platinum (1)
- pluripotent (1)
- positionalskull deformities (1)
- positron emission tomography/computed tomography (1)
- postoperative Phase (1)
- presynaptic plasticity (1)
- prevention (1)
- primary cell culture (1)
- progenitors (1)
- prognostic marker (1)
- proliferation (1)
- prostacyclins (1)
- proteins (1)
- pränatal (1)
- psychiatric disorders (1)
- pterionaler Zugang (1)
- pyramidal neurons (1)
- quality of life (1)
- radiation therapy (1)
- randomized controlled double-blind study (1)
- rare bone disease (1)
- ratten (1)
- real time PCR (1)
- receptor tyrosine kinase (1)
- recombinat-human-erythropoietin (1)
- reflex (1)
- regional blood flow (1)
- regional blood ftow (1)
- regression (1)
- rehabilitation (1)
- release (1)
- renin (1)
- resilience (1)
- resistance (1)
- respiration (1)
- reveals (1)
- rickets (1)
- sagittal synostosis (1)
- scale (1)
- scaphocephaly (1)
- schizophrenia (1)
- secondary brain damage (1)
- senescence (1)
- serotonin (1)
- shock (1)
- skull base (1)
- slice culture (1)
- specification (1)
- spinal tumor operation (1)
- spine (1)
- spontane (1)
- spontaneous regression (1)
- stereotaxy (1)
- stress (1)
- stress signaling (1)
- stroke (1)
- stroke therapy (1)
- subarachnoid hemorrhage (1)
- subarachnoid hemorrhage (SAH) (1)
- subjective perception (1)
- super-resolution microscopy (1)
- suppressor (1)
- surgery (1)
- sympathetic nerve activity. (1)
- synaptic ultrastructure (1)
- tPA (1)
- targeted therapy (1)
- taxanes (1)
- temporal bone (1)
- therapy response (1)
- thiosemicarbazone (1)
- three-dimensional (1)
- three-dimensional imaging (1)
- threshold criterion (1)
- threshold level (1)
- thromboinflammation (1)
- thrombosis (1)
- thymectomized rats (1)
- tnf (1)
- total peripheral resistance (1)
- transcranial motor-evoked potentials (1)
- transient ischemic attack (1)
- tumor (1)
- tumor development (1)
- tumor slice cultures (1)
- tumor treating fields (1)
- tumor-invasion (1)
- tumor-necrosis-factor (1)
- tumormicroenvironment (1)
- uPA (1)
- vascularisation (1)
- vasopressin (1)
- vertebral pedicles (1)
- vincristine (1)
- vitamin K antagonists (1)
- von Willebrand factor (1)
- warfarin (1)
- weight drop (1)
- µ opioid receptors (1)
- µ·Opioid receptor subtypes (1)
- ästhetische Ergebnisse (1)
- β-APP (1)
Institute
- Neurochirurgische Klinik und Poliklinik (214)
- Pathologisches Institut (21)
- Neurologische Klinik und Poliklinik (18)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (11)
- Physiologisches Institut (9)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Theodor-Boveri-Institut für Biowissenschaften (6)
- Klinik und Poliklinik für Unfall-, Hand-, Plastische und Wiederherstellungschirurgie (Chirurgische Klinik II) (5)
- Graduate School of Life Sciences (4)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (4)
Sonstige beteiligte Institutionen
Introduction
Stimulation settings of deep brain stimulation (DBS) have evolved empirically within a limited parameter space dictated by first generation devices. There is a need for controlled clinical studies, which evaluate efficacy and safety of established programming practice against novel programming options provided by modern neurostimulation devices.
Methods
Here, we tested a polarity reversal from conventional monopolar cathodic to anodic stimulation in an acute double-blind, randomized, cross-over study in patients with PD implanted with bilateral STN DBS. The primary outcome measure was the difference between efficacy and side-effect thresholds (current amplitude, mA) in a monopolar review and the severity of motor symptoms (as assessed by MDS-UPDRS III ratings) after 30 min of continuous stimulation in the medication off-state.
Results
Effect and side effect thresholds were significantly higher with anodic compared to cathodic stimulation (3.36 ± 1.58 mA vs. 1.99 ± 1.37 mA; 6.05 ± 1.52 mA vs. 4.15 ± 1.13 mA; both p < 0.0001). However, using a predefined amplitude of 0.5 mA below the respective adverse effect threshold, blinded MDS-UPDRS-III-ratings were significantly lower with anodic stimulation (anodic: median 17 [min: 12, max: 25]; cathodic: 23 [12, 37]; p < 0.005).
Conclusion
Effective anodic stimulation requires a higher charge injection into the tissue, but may provide a better reduction of off-period motor symptoms within the individual therapeutic window. Therefore, a programming change to anodic stimulation may be considered in patients suffering from residual off-period motor symptoms of PD despite reaching the adverse effect threshold of cathodic stimulation in the subthalamic nucleus.
Tumor treating fields (TTFields) are approved for glioblastoma (GBM) therapy. TTFields disrupt cell division by inhibiting spindle fiber formation. Spindle assembly checkpoint (SAC) inhibition combined with antimitotic drugs synergistically decreases glioma cell growth in cell culture and mice. We hypothesized that SAC inhibition will increase TTFields efficacy. Human GBM cells (U-87 MG, GaMG) were treated with TTFields (200 kHz, 1.7 V/cm) and/or the SAC inhibitor MPS1-IN-3 (IN-3, 4 µM). Cells were counted after 24, 48, and 72 h of treatment and at 24 and 72 h after end of treatment (EOT). Flow cytometry, immunofluorescence microscopy, Annexin-V staining and TUNEL assay were used to detect alterations in cell cycle and apoptosis after 72 h of treatment. The TTFields/IN-3 combination decreased cell proliferation after 72 h compared to either treatment alone (−78.6% vs. TTFields, P = 0.0337; −52.6% vs. IN-3, P = 0.0205), and reduced the number of viable cells (62% less than seeded). There was a significant cell cycle shift from G1 to G2/M phase (P < 0.0001). The apoptotic rate increased to 44% (TTFields 14%, P = 0.0002; IN-3 4%, P < 0.0001). Cell growth recovered 24 h after EOT with TTFields and IN-3 alone, but the combination led to further decrease by 92% at 72 h EOT if IN-3 treatment was continued (P = 0.0288). The combination of TTFields and SAC inhibition led to earlier and prolonged effects that significantly augmented the efficacy of TTFields and highlights a potential new targeted multimodal treatment for GBM.
Vestibular schwannoma (VS) are benign cranial nerve sheath tumors of the vestibulocochlear nerve. Their incidence is mostly sporadic, but they can also be associated with NF2-related schwannomatosis (NF2), a hereditary tumor syndrome. Metastasis associated in colon cancer 1 (MACC1) is known to contribute to angiogenesis, cell growth, invasiveness, cell motility and metastasis of solid malignant cancers. In addition, MACC1 may be associated with nonsyndromic hearing impairment. Therefore, we evaluated whether MACC1 may be involved in the pathogenesis of VS. Sporadic VS, recurrent sporadic VS, NF2-associated VS, recurrent NF2-associated VS and healthy vestibular nerves were analyzed for MACC1 mRNA and protein expression by quantitative polymerase chain reaction and immunohistochemistry. MACC1 expression levels were correlated with the patients’ clinical course and symptoms. MACC1 mRNA expression was significantly higher in sporadic VS compared to NF2-associated VS (p < 0.001). The latter expressed similar MACC1 concentrations as healthy vestibular nerves. Recurrent tumors resembled the MACC1 expression of the primary tumors. MACC1 mRNA expression was significantly correlated with deafness in sporadic VS patients (p = 0.034). Therefore, MACC1 might be a new molecular marker involved in VS pathogenesis.
Background
Hematogenous tumor spread of malignant meningiomas occurs very rarely but is associated with very poor prognosis.
Case presentation
We report an unusual case of a patient with a malignant meningioma who developed multiple metastases in bones, lungs and liver after initial complete resection of the primary tumor. After partial hepatic resection, specimens were histologically analyzed, and a complete loss of E-cadherin adhesion molecules was found. No oncogenic target mutations were found. The patient received a combination of conventional radiotherapy and peptide receptor radionuclide therapy (PRRT). Due to aggressive tumor behavior and rapid spread of metastases, the patient deceased after initiation of treatment.
Conclusions
E-cadherin downregulation is associated with a higher probability of tumor invasion and distant metastasis formation in malignant meningioma. Up to now, the efficacy of systemic therapy, including PRRT, is very limited in malignant meningioma patients.
Highlights
• Beta-Guided programming is an innovative approach that may streamline the programming process for PD patients with STN DBS.
• While preliminary findings from our study suggest that Beta Titration may potentially mitigate STN overstimulation and enhance symptom control,
• Our results demonstrate that beta-guided programming significantly reduces programming time, suggesting it could be efficiently integrated into routine clinical practice using a commercially available patient programmer.
Background
Subthalamic nucleus deep brain stimulation (STN-DBS) is an effective treatment for advanced Parkinson's disease (PD). Clinical outcomes after DBS can be limited by poor programming, which remains a clinically driven, lengthy and iterative process. Electrophysiological recordings in PD patients undergoing STN-DBS have shown an association between STN spectral power in the beta frequency band (beta power) and the severity of clinical symptoms. New commercially-available DBS devices now enable the recording of STN beta oscillations in chronically-implanted PD patients, thereby allowing investigation into the use of beta power as a biomarker for DBS programming.
Objective
To determine the potential advantages of beta-guided DBS programming over clinically and image-guided programming in terms of clinical efficacy and programming time.
Methods
We conducted a randomized, blinded, three-arm, crossover clinical trial in eight Parkinson's patients with STN-DBS who were evaluated three months after DBS surgery. We compared clinical efficacy and time required for each DBS programming paradigm, as well as DBS parameters and total energy delivered between the three strategies (beta-, clinically- and image-guided).
Results
All three programming methods showed similar clinical efficacy, but the time needed for programming was significantly shorter for beta- and image-guided programming compared to clinically-guided programming (p < 0.001).
Conclusion
Beta-guided programming may be a useful and more efficient approach to DBS programming in Parkinson's patients with STN-DBS. It takes significantly less time to program than traditional clinically-based programming, while providing similar symptom control. In addition, it is readily available within the clinical DBS programmer, making it a valuable tool for improving current clinical practice.
Purpose
Diaschisis of cerebrocerebellar loops contributes to cognitive and motor deficits in pediatric cerebellar brain tumor survivors. We used a cerebellar white matter atlas and hypothesized that lesion symptom mapping may reveal the critical lesions of cerebellar tracts.
Methods
We examined 31 long-term survivors of pediatric posterior fossa tumors (13 pilocytic astrocytoma, 18 medulloblastoma). Patients underwent neuronal imaging, examination for ataxia, fine motor and cognitive function, planning abilities, and executive function. Individual consolidated cerebellar lesions were drawn manually onto patients’ individual MRI and normalized into Montreal Neurologic Institute (MNI) space for further analysis with voxel-based lesion symptom mapping.
Results
Lesion symptom mapping linked deficits of motor function to the superior cerebellar peduncle (SCP), deep cerebellar nuclei (interposed nucleus (IN), fastigial nucleus (FN), ventromedial dentate nucleus (DN)), and inferior vermis (VIIIa, VIIIb, IX, X). Statistical maps of deficits of intelligence and executive function mapped with minor variations to the same cerebellar structures.
Conclusion
We identified lesions to the SCP next to deep cerebellar nuclei as critical for limiting both motor and cognitive function in pediatric cerebellar tumor survivors. Future strategies safeguarding motor and cognitive function will have to identify patients preoperatively at risk for damage to these critical structures and adapt multimodal therapeutic options accordingly.
Introduction
In spinal surgery, precise instrumentation is essential. This study aims to evaluate the accuracy of navigated, O-arm-controlled screw positioning in thoracic and lumbar spine instabilities.
Materials and methods
Posterior instrumentation procedures between 2010 and 2015 were retrospectively analyzed. Pedicle screws were placed using 3D rotational fluoroscopy and neuronavigation. Accuracy of screw placement was assessed using a 6-grade scoring system. In addition, screw length was analyzed in relation to the vertebral body diameter. Intra- and postoperative revision rates were recorded.
Results
Thoracic and lumbar spine surgery was performed in 285 patients. Of 1704 pedicle screws, 1621 (95.1%) showed excellent positioning in 3D rotational fluoroscopy imaging. The lateral rim of either pedicle or vertebral body was protruded in 25 (1.5%) and 28 screws (1.6%), while the midline of the vertebral body was crossed in 8 screws (0.5%). Furthermore, 11 screws each (0.6%) fulfilled the criteria of full lateral and medial displacement. The median relative screw length was 92.6%. Intraoperative revision resulted in excellent positioning in 58 of 71 screws. Follow-up surgery due to missed primary malposition had to be performed for two screws in the same patient. Postsurgical symptom relief was reported in 82.1% of patients, whereas neurological deterioration occurred in 8.9% of cases with neurological follow-up.
Conclusions
Combination of neuronavigation and 3D rotational fluoroscopy control ensures excellent accuracy in pedicle screw positioning. As misplaced screws can be detected reliably and revised intraoperatively, repeated surgery for screw malposition is rarely required.
Traumatic brain injury (TBI) is the leading cause of death and disability in polytrauma and is often accompanied by concomitant injuries. We conducted a retrospective matched-pair analysis of data from a 10-year period from the multicenter database TraumaRegister DGU\(^®\) to analyze the impact of a concomitant femoral fracture on the outcome of TBI patients. A total of 4508 patients with moderate to critical TBI were included and matched by severity of TBI, American Society of Anesthesiologists (ASA) risk classification, initial Glasgow Coma Scale (GCS), age, and sex. Patients who suffered combined TBI and femoral fracture showed increased mortality and worse outcome at the time of discharge, a higher chance of multi-organ failure, and a rate of neurosurgical intervention. Especially those with moderate TBI showed enhanced in-hospital mortality when presenting with a concomitant femoral fracture (p = 0.037). The choice of fracture treatment (damage control orthopedics vs. early total care) did not impact mortality. In summary, patients with combined TBI and femoral fracture have higher mortality, more in-hospital complications, an increased need for neurosurgical intervention, and inferior outcome compared to patients with TBI solely. More investigations are needed to decipher the pathophysiological consequences of a long-bone fracture on the outcome after TBI.
The metastatic suppressor BRMS1 interacts with critical steps of the metastatic cascade in many cancer entities. As gliomas rarely metastasize, BRMS1 has mainly been neglected in glioma research. However, its interaction partners, such as NFκB, VEGF, or MMPs, are old acquaintances in neurooncology. The steps regulated by BRMS1, such as invasion, migration, and apoptosis, are commonly dysregulated in gliomas. Therefore, BRMS1 shows potential as a regulator of glioma behavior. By bioinformatic analysis, in addition to our cohort of 118 specimens, we determined BRMS1 mRNA and protein expression as well as its correlation with the clinical course in astrocytomas IDH mutant, CNS WHO grade 2/3, and glioblastoma IDH wild-type, CNS WHO grade 4. Interestingly, we found BRMS1 protein expression to be significantly decreased in the aforementioned gliomas, while BRMS1 mRNA appeared to be overexpressed throughout. This dysregulation was independent of patients’ characteristics or survival. The protein and mRNA expression differences cannot be finally explained at this stage. However, they suggest a post-transcriptional dysregulation that has been previously described in other cancer entities. Our analyses present the first data on BRMS1 expression in gliomas that can provide a starting point for further investigations.